Jonathan Marmur, MD, FACC, FRCP

Dr. Jonathan D. Marmur is a Professor of Medicine, and Director of the Cardiac Catheterization Laboratory at SUNY Downstate Medical Center in Brooklyn, NY. Dr. Marmur received his MD in 1982 from Laval University in Quebec City, Canada.  Thereafter, he completed his medical residency in Internal Medicine at McGill University, followed by a Cardiology Fellowship at the University of Toronto.  He then obtained funding from a variety of agencies (Ontario Heart and Stroke Foundation, Medical Research Council of Canada, US National Institutes of Health) to support his basic science research and clinical work in the field of Interventional Cardiology at the Mount Sinai Medical Center, NY.

In addition to training hundreds of physicians in the field of Interventional Cardiology, Dr. Marmur has served on the Editorial Boards of the Journal of the American College of Cardiology, the Journal of Cardiovascular Revascularization Medicine, and the Journal of Invasive Cardiology. His earlier work focused on the vascular response to injury using a variety of devices, including balloon angioplasty, directional coronary atherectomy, and excimer laser. A recognized expert in coagulation, he has also contributed to the basic science and clinical literature on hemostasis and thrombosis. Dr. Marmur and his colleagues hold a patent on a novel biomarker (TIMP; tissue inhibitor of metalloproteinase) that has the ability to predict future adverse events such as myocardial infarction and death. Dr. Marmur's research also involves the areas of gene therapy and genomics. As one of the early pioneers in the application of recombinant DNA and viral vector technologies to human arterial disease, Dr. Marmur recognizes that future advances are most likely to be derived from the field of genomics and the related subfields of functional genomics, proteomics, and bioinformatics. His current research efforts are focused on the generation of the Downstate Cath Lab GeneBank, a repository of molecular genetics, angiographic and historical information on patients who have undergone Cardiac Catheterization.

Education

• Medical School: Laval University
• Internship: McGill University
• Residency: McGill University
• Fellowship: University of Toronto and Mount Sinai Medical Center

Research Interests

• Hemostasis and thrombosis
• Genetic and proteomic biomarkers of cardiovascular prognosis

Patents

Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) is an Independent Predictor of All-Cause Mortality, Cardiac Mortality, and Myocardial Infarction. Submitted December 2, 2004 by The Research Foundation of the State University of New York (SUNY). For more information, visit: www.RFSUNY.org.

Current Grants

1. Source: Pfizer, Inc.
   • Title: ACT-guided Titration of Low Molecular Weight Heparin Dosing in Percutaneous Coronary Intervention
   • Period of Support: 2003-present
   • Role: Principal Investigator
   • Total Cost of Project: $600,000
2. Source: National Institutes of Health
   • Grant Number: 1R21HL098661-01
   • Title: Plasma F11R and Cardiovascular Outcomes in Patients with Coronary Artery Disease
   • Period of Support: 03/01/2010 - 02/29/2012
   • Role: Collaborator (Principal Investigator: Dr. Erdal Cavusoglu)
   • Aim: The major aim of this project is to investigate the role of F11R in patients with established coronary artery disease
3. Source: American Heart Association (Founders Affiliate)
   • Grant Number: 10GRNT3700003 (Grant-in-Aid)
   • Title: Endogenous Erythropoietin and Outcome in Coronary Artery Disease
   • Period of Support: 07/01/2010 - 06/30/2013
   • Role: Collaborator (Principal Investigator: Dr. Erdal Cavusoglu)
   • Aim: The major aim of this project is to determine the prognostic significance of erythropoietin in patients with the acute coronary syndromes

Past Grants

1. Principal investigator: Jonathan D. Marmur
   • source: Ontario Heart and Stroke Foundation
   • title of project: Biologic Response to Vascular Injury
   • dates of project: 1988-1990
   • total direct cost of project $70,000
2. Principal investigator: Jonathan D. Marmur
   • source: Medical Research Council of Canada Fellowship Award (9211FER-1033-34668)
   • title of project: Molecular Responses to Vascular Injury
   • dates of grant: 1990-1994
   • total direct cost of project $202,000
3. Principal investigator: Jonathan D. Marmur
   • source: NIH/NHLBI (KO8 HL03210-01)
   • title of project: Tissue Factor Regulation In Arterial Injury
   • dates of project: 1994-1999
   • total direct cost of project $436,590
4. Principal investigator: Jonathan D. Marmur
   • source: Novo Nordisc
   • title of project: FFR-rFVII in Patients Undergoing Elective PTCA-ACES
   • dates of project: 1999-2001
   • total direct cost of project $65,750
5. Local (Mt. Sinai Hospital, NY) principal investigator: Jonathan D. Marmur
   • source: Berlex Laboratories
   • title of project: Adenovirus Mediated Human FGF4 Gene Transfer in Patients with Angina Pectoris
   • dates of project: 1998-2001
   • total direct cost of project $155,000
6. Principal investigator: Jonathan D. Marmur
   • source: Pharmacia & Upjohn
   • title of project: Dalteparin Reopro ACT Monitoring (DREAM)
   • dates of project: 2000-2003
   • total direct cost of project $182,000
7. Local (Mt. Sinai Hospital, NY) principal investigator: Jonathan D. Marmur
   • source: Berlex Laboratories
   • title of project: A Multicenter, Randomized Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ad5FGF-4 in Patients with Stable Angina
   • dates of project: 2000-2003
   • total direct cost of project $181,000

• Zhang M, Hou YJ, Cavusoglu E, Lee DC, Steffensen R, Yang L, Bashari D, Villamil J, Moussa M, Fernaine G, Jensenius JC, Marmur JD, Ko W, Shevde K. MASP-2 activation is involved in ischemia-related necrotic myocardial injury in humans. Int JCardiol. 2013 Jun 20;166(2):499-504.
• Law S, Panichpisal K, Demede M, John S, Marmur JD, Nath J, Baird AE. ContrastInduced Neurotoxicity following Cardiac Catheterization. Case Rep Med 2012;2012:267860
• Ko W, Tranbaugh R, Marmur JD, Supino PG, Borer JS. Myocardial Revascularization in New York State: Variations in the PCI-to-CABG Ratio and Their Implications. J Am Heart Assoc. 2012 Apr; 1(2):e001446.
• Cavusoglu E, Marmur JD, Hojjati MR, Chopra V, Butala M, Subnani R, Huda MS, Yanamadala S, Ruwende C, Eng C, Pinsky DJ. Plasma interleukin-10 levels and adverse outcomes in acute coronary syndrome. Am J Med. 2011 Aug;124(8):724-30.
• Azari BM, Marmur JD, Salifu MO, Ehrlich YH, Kornecki E, Babinska A. Transcription and translation of human F11R gene are required for an initial step of atherogenesis induced by inflammatory cytokines. J Transl Med. 2011;9:98.
• Azari BM, Marmur JD, Salifu MO, Cavusoglu E, Ehrlich YH, Kornecki E, Babinska A. Silencing of the F11R gene reveals a role for F11R/JAM-A in the migration of inflamed vascular smooth muscle cells and in atherosclerosis. Atherosclerosis. 2010;212:197-205.
• Cavusoglu E, Ruwende C, Chopra V, Poludasu S, Yanamadala S, Frishman WH, Eng C, Pinsky DJ, Marmur JD. Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiography. Atherosclerosis. 2010;210:226-31.
• Poludasu S, Cavusoglu E, Khan W, Marmur JD. Neutrophil to lymphocyte ratio as a predictor of long-term mortality in African Americans undergoing percutaneous coronary intervention. Clin Cardiol. 2009;32:E6-E10.
• Marmur JD, Bullock-Palmer RP, Poludasu S, Cavusoglu E. Avoiding intelligence failures in the cardiac catheterization laboratory: Strategies for the safe and rational use of dalteparin or enoxaparin during percutaneous coronary intervention. J Invasive Cardiol. 2009;21:653-64.
• Poludasu S, Marmur JD, Weedon J, Khan W, Cavusoglu E. Red cell distribution width (RDW) as a predictor of long-term mortality in patients undergoing percutaneous coronary intervention. Thromb Haemost. 2009;102:581-7.
• Cavusoglu E, Marmur JD, Chhabra S, Chopra V, Eng C, Jiang XC. Relation of baseline plasma phospholipid transfer protein (PLTP) activity to left ventricular systolic dysfunction in patients referred for coronary angiography. Atherosclerosis. 2009;207:261-5.
• Cavusoglu E, Chopra V, Gupta A, Choksi PU, Ruwende C, Yanamadala S, Frishman WH, Pinsky DJ, Marmur JD. Relation of baseline serum potassium levels to angiographic findings in patients with known or suspected coronary artery disease. Am J Hypertens. 2009;22:754-62.
• Poludasu S, Marmur JD, Weedon J, Khan W, Cavusoglu E. Effect of hemoglobin level on long-term all-cause mortality after percutaneous coronary intervention in . Am J Cardiol. 2009;103:1078-82. Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Pinsky DJ, Marmur JD. Relationship of baseline plasma ADMA levels to cardiovascular outcomes at 2 years in men with acute coronary syndrome referred for coronary angiography. Coron Artery Dis. 2009;20:112-117.
• Marmur JD, Poludasu S, Lazar J, Cavusoglu E. Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention. Catheter Cardiovasc Interv. 2009;73:214-221.
• Cavusoglu E, Chopra V, Gupta A, Battala VR, Poludasu S, Eng C, Marmur JD. Relation between red blood cell distribution width (RDW) and all-cause mortality at two years in an unselected population referred for coronary angiography. Int J Cardiol. 2009 Jan 12.